The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s oral biologics & biosimilars market report forecasts the oral biologics & biosimilars market size to grow to $13.68 Billion by 2027, with a CAGR (compound annual growth rate) of more than 20%.

Learn More On The Oral Biologics & Biosimilars Market Report 2023 – https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

Oral Biologics & Biosimilars Market Size Forecast
The global oral biologics & biosimilars market is expected to grow from $5.37 billion in 2022 to $6.47 billion in 2023 at a compound annual growth rate (CAGR) of 20.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oral biologics and biosimilars market size is expected to grow from $13.68 billion in 2027 at a CAGR of 20.6%.

North America held the largest oral biologics & biosimilars market share, and Middle East was the fastest-growing region in 2022.

Key Oral Biologics & Biosimilars Market Driver ­– Rise In The Prevalence Of Chronic Diseases Such As Arthritis, Asthma, And Cancer
According to a United Nations article, a US-based intergovernmental organization, by 2030, chronic diseases are predicted to account for 70% of all fatalities worldwide. It is anticipated that chronic disease will account for nearly 60% of all deaths worldwide. Therefore, the rise in the prevalence of chronic diseases is driving the growth of the biologics and biosimilar market.

Request for A Sample Of The Global Oral Biologics & Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

Key Oral Biologics & Biosimilars Market Trend – Creating New Insulin Biosimilar
The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin to capture the market share. For instance,In November 2021, Biocon, an India-based biopharmaceutical company launched inter-changeable biosimilar insulin. These products help to control high blood sugar in pediatric patients with type 1 diabetes and adults with type 2 diabetes and are available in a vial and prefilled pen presentations. These are interchangeable for the reference brand, Lantus (insulin glargine), allowing for substitution at the pharmacy counter. Thus, companies in the oral biologics and biosimilar market are investing in the trend of developing biosimilar of insulin to gain profit.

Oral Biologics & Biosimilars Market Segment
1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, and Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Other Diseases
3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, and Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

Oral Biologics & Biosimilars Market Major Players and Strategies
Major players in the oral biologics & biosimilars market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan plc, and Emisphere Technologies.

The Oral Biologics & Biosimilars Global Market Report 2023 covers regional data on oral biologics & biosimilars market size, oral biologics & biosimilars market trends and drivers, opportunities, strategies, and oral biologics & biosimilars market competitor analysis. The countries covered in the oral biologics & biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Biologics are drugs made from living cells using highly complex technology, while biosimilars are created to function similarly to biologics but are not identical to biologics. Oral biologics and biosimilar market comprise biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer’s, multiple sclerosis, HIV/AIDS, and other serious conditions and are used to treat chronic diseases such as diabetes, arthritis, and cancer.

View More Reports Related To The Oral Biologics & Biosimilars Market –
Biosimilars Global Market Report 2023
Biologics Global Market Report 2023
Oral Biologics & Biosimilar Drugs Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: